Is bitemporal ECT more effective than bifrontal ECT in reducingthe symptoms of depression in adults? by Brinton, Talia M.
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship Student Dissertations, Theses and Papers
2015
Is bitemporal ECT more effective than bifrontal
ECT in reducingthe symptoms of depression in
adults?
Talia M. Brinton
Philadelphia College of Osteopathic Medicine, Taliabr@pcom.edu
Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Medicine and Health Sciences Commons
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Brinton, Talia M., "Is bitemporal ECT more effective than bifrontal ECT in reducingthe symptoms of depression in adults?" (2015).
PCOM Physician Assistant Studies Student Scholarship. Paper 211.
  
 
 
 
 
 
Is bitemporal ECT more effective than bifrontal ECT in reducing 
the symptoms of depression in adults? 
 
 
 
 
 
 
Talia M. Brinton, PA-S  
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 
 
 
December 19, 2014 
  
 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
bitemporal ECT is more effective than bifrontal ECT in the treatment of adults with major 
depressive disorder.  
 
STUDY DESIGN: Review of three published randomized controlled trials, all English language. 
All RCTs were published after 1999 and studied patients older than 17 years old.  
 
DATA SOURCES: Three randomized control trials were found using PubMED, OVID, and 
Medline. Articles were selected based on relevance and that the outcomes of the studies mattered 
to patients.   
 
OUTCOME(S) MEASURED: Hamilton Rating Scale for Depression- 24 item completed by 
practitioner.   
 
RESULTS: The results of the Kellner6 study was that bitemporal ECT placement had an average 
change in HRSD-24 score of 22.4 points, from 33.7 to 11.3 (P<0.0001), and a remission rate of 
64% (95% CI 53-75%). Bitemporal ECT was 3% more effective than bifrontal ECT for treating 
depression. 6  The Bailine2 study concluded that bitemporal ECT placement had an average 
change in HRSD-24 score of 22.7 points, from 27.7 to 5.0 and a remission rate of 95.8%. 
Bifrontal ECT was 4.2% more effective than bitemporal ECT for treating depression. 2 The 
Ranjkesh8 study reported that bitemporal ECT placement had an average change in HRSD-24 
score of 24.3 points, from 32.1 to 7.8, and a remission rate of 100%. There was no difference in 
effectiveness when comparing bitemporal ECT to bifrontal ECT.8 
 
CONCLUSIONS: The results of the three randomized controlled trials found that bitemporal 
ECT and bifrontal ECT are effective in the treatment of adults with major depressive disorder. 
The analysis of the three randomized controlled trials is inconclusive to whether bitemporal is 
more effective than bifrontal ECT in treating adults with major depressive disorder.   
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INTRODUCTION 
Electroconvulsive therapy (ECT) is predominately used to treat severe depression. After 
the administration of general anesthesia, a small electric current is given via electrodes to the 
patient to produce a generalized cerebral seizure. 1 This paper evaluates three randomized 
controlled trials (RCTs) comparing the effectiveness of bitemporal electrode ECT placement for 
the treatment of severe depression with other electrode ECT placements. 
This topic/question is relevant to practicing PA and patients because of the high 
prevalence and significant number of health care visits each year for major depressive disorder. 
Major depression affects 16.6% of the US population and is the leading cause of disability in 
Western countries between ages 15-44 years old. 2 ECT costs vary but range from $300-$800 per 
treatment. After eight sessions (average number to completion), the total cost is $2400-$6400 per 
patient. 3 8.0 million people visited a physician office or ER with major depressive disorder as 
the primary diagnosis in 2009-2010. 4 
The exact cause of depression is unknown but is thought to be a combination of genetics, 
dysregulation of neurotransmitters (specifically serotonin, norepinephrine, and dopamine), 
immunologic abnormalities, and social/psychological factors. 5 Symptoms of depression include 
depressed mood, anhedonia, physical symptoms (fatigue, appetite problem, psychomotor 
changes, sleep disorder), and psychological symptoms (difficulty concentrating, guilt, thoughts 
of death). 5 
The usual methods of treatment for major depression include a combination of 
psychotherapy and pharmacology. The first line pharmacological agents are selective serotonin 
reuptake inhibitors (SSRI) that include fluoxetine, paroxetine, sertraline, citalopram, 
escitalopram. Alternative antidepressant agents are serotonin norepinephrine reuptake inhibitors 
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(SNRIs) :venlafaxine, duloxetine;  noradrenergic and specific serotonergic antidepressant 
(NaSSa): mirtazapine; norepinephrine dopamine reuptake inhibitors (NDRI): buproprion; and 
tricyclic antidepressants (TCA); amitriptyline, and nortriptyline 5.  
Select patients have refractory cases of depression that cannot be managed by the 
treatment options mentioned above. The method of treatment is being proposed because the use 
of ECT has been shown to be effective in the treatment of major depressive disorder in adults 
who have not benefited or been treated adequately with traditional psychotherapy and 
pharmacology.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not bitemporal 
ECT is more effective than bifrontal ECT in the treatment of adults with major depressive 
disorder 
METHODS 
The population studied was men and women with severe depression older than 17 years 
of age. The intervention studied was bitemporal ECT. All three randomized control studies being 
used compared bitemporal ECT to bifrontal ECT therapy. Outcomes were measured on the 
severity of depression as rated on the Hamilton Depression Score that was completed by a 
practitioner.  
Keywords used in the search to find these studies were ECT, bitemporal, and depression. 
All articles were published in peer-reviewed journals and in English. The author researched the 
articles via Medline, PubMed, and OVID search engines. Articles were selected based on 
relevance and that the outcomes of the studies mattered to patients (POEMs). The inclusion 
criteria included studies that were RCTs published after 1999. The exclusion criteria included pts 
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under the age of 17 years old.  Summary statistics were reported or used RBI, ABI, NNT, and p-
values.  
Table 1 - Demographics & Characteristics of included studies 
Study Type #Pts Age Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Ranjkesh
6 (2005) 
RCT 45 >18 Score greater 
than 16 on the 
HDRS score 
greater, more 
than 2 days' 
antidepressant 
discontinuation 
for a wash-out 
period 
history of ECT during the 
preceding 3-month 
period, taking 
nonbenzodiazepine 
anticonvulsants, 
lidocaine, theophylline, or 
lithium, a history of 
psychiatric disorders not 
related to a mood disorder 
 
6 Bitemporal, 
Right 
unilateral, 
bifrontal ECT 
placement 
Bailine7 
(2000) 
RCT 58 >17 score higher 
than 17 on the 
HRDS, score 
higher than 2 on 
the first item 
(sad mood), 
score higher 
than 24 on the 
standardized 
Mini-Mental 
State 
history of any other 
psychiatric disorder not 
related to a mood 
disorder, ECT within the 
past 6 months, use of 
psychotropic medication, 
except up to 3 mg/day of 
lorazepam as needed for 
agitation or anxiety 
10 Bitemporal, 
bifrontal ECT 
placement 
Kellner 8 
(2010) 
RCT 230 20-
87 
Score higher 
than 21 on the 
HRDS, ability 
to cooperate in 
detailed 
neuropsychologi
cal testing, 
referred for 
ECR for 
primary major 
depressive 
disorder or 
bipolar disorder, 
w or w/o 
psychosis 
History of any psychiatric 
disorder not related to a 
mood disorder, a mood 
disorder that was not 
depression before this 
episode of depression, any 
disease affecting 
cognition, substance 
abuse in the last 6 months, 
medical conditions 
contraindicating ECT, 
ECT in the last 6 months, 
MMSE >21 
63 Bitemporal, 
Right 
unilateral, 
bifrontal ECT 
placement 
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OUTCOMES MEASURED 
 Study outcomes measured were the severity of depression. Outcomes were measure by 
using the Hamilton Rating Scale for Depression- 24 (HRSD-24) item completed by practitioner. 
Practitioner assigns a number to the severity of symptoms. Symptoms assessed include: 
depressed mood, feelings of guilt, suicide, insomnia early, insomnia middle, insomnia late, work 
and activities, psychomotor retardation, agitation, anxiety (psychological), anxiety somatic, 
somatic symptoms (gastrointestinal), somatic symptoms general, genital symptoms, 
hypochondriasis, loss of weight, insight, diurnal variation, depersonalization and derealization, 
paranoid symptoms, obsessional and compulsive symptoms. 
 Kellner et al measured outcome was the severity of depression using continuous HRDS-
24 scores approximately three times a week and a single end of treatment HRSD-24 score within 
24-36 hours of the final ECT. 8 
Bailine et al measured outcomes were the severity of depression using the HRSD-24 
score, severity of symptoms in depression using the Clinical Global Impression scale, and 
cognitive impairment using the standardized Mini Mental scores at baseline and 24 hours after 
each treatment. 7 
Ranjkesh et al measured outcomes were the severity of depression using the HRSD-24 
score, and cognitive impairment using the standardized Mini Mental scores. These were assessed 
before receiving the initial ECT session, before the fourth ECT session, and on day after the 
eighth ECT session. A clinical psychologist unaware of the ECT electrode placement performed 
the tests at approximately 8 am. 6 
RESULTS 
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 The three studies compared bitemporal ECT to bifrontal ECT placement. All trials were 
done on adults > 17 yo.  
 The Kellner8 study was a randomized control, double blind, comparison trial that 
randomized 230 subjects into groups receiving right unilateral ECT (77 patients), bifrontal ECT 
(81 patients), and bitemporal ECT (72 patients). Each patient was treated with their assigned 
ECT electrode placement until they reached pre-specified remission criteria, then patients were 
followed naturalistically for 2 months. Of the 230 participants who entered the trial, 63 (27.4%) 
exited the study early due to confusion/cognitive impairment, ECT not working, non cognitive-
side effect, and improvement in condition. “Worst-case” analysis was not done on the 
participants that did not complete the trial. There was no statistically significant difference 
between the participants in all three trial groups as determined by the general linear model. 
(P<0.0001). The mean age of the participants was 53 years old, 63.5% female, and 95.5 % of 
participants were white. In regards to the severity of their depression, the participants initially 
had a mean HRSD-24 baseline of 34.6, the average length of their current depressive episode 
was 2.4 years, and they had an average of 4.6 psychiatric admissions. Patients were treated with 
ECT until pre-specified remission criteria and were assessed with the HRSD-24 at baseline, the 
fourth ECT, and the last ECT, 1 week after the last ECT, and 2 months after the last ECT. After 
completion of the study, all three electrode placements had statistically significantly decrease in 
symptoms of depression.  Right unilateral ECT placement had an average change in HRSD-24 
score of 21.0 points, from 34.9 to 13.9 (P<0.0001), and a remission rate of 55% (95% CI 43-
66%). Bifrontal ECT placement had an average change in HRSD-24 score of 23.4 points, from 
35.1 to 11.7 (P<0.0001), and a remission rate of 61% (95% CI 50-71%). Bitemporal ECT 
placement had an average change in HRSD-24 score of 22.4 points, from 33.7 to 11.3 
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(P<0.0001), and a remission rate of 64% (95% CI 53-75%). Table 2 shows the treatment effects 
of bitemporal ECT on the symptoms of depression, when compared to bifrontal ECT as control. 
Relative benefit increase (RBI) was calculated to be 0.05. Absolute benefit increase (ABI) was 
calculated to be 3%. Numbers needed to treat (NNT) was calculated as 33, indicating that 33 
patients need to be treated with bitemporal ECT rather then bifrontal ECT to see one more 
patient have remission of depressive symptoms 8 weeks after their last ECT treatment. 8 
Table 2: Treatment effect of bitemporal ECT on depression  
CER EER RBI ABI NNT P 
61% 64% 0.05 3% 33 0.0001 
 
The Bailine7 study was a randomized control, double blind, comparison trial that randomized 58 
subjects into groups receiving bifrontal ECT (24 patients), and bitemporal ECT (24 patients), 10 
patients did not complete the study due to medical problems unrelated to ECT, two require 
antipsychotic medication, two discharged before completing the study. ‘Worst-case’ analysis was 
not done on the participants that did not complete the trial by the 12th treatment, 24/24 patients in 
the bifrontal ECT group and 23/24 patients in the bitemporal ECT group met remission criteria 
for depression. There was no statistically significant difference between the participants of each 
group as analyzed with chi-square tests for categorical variables and t test for continuous 
variables . (P= 0.90). The mean age of the participants was 52.86 years old and 53.3% female. In 
regards to the severity of their depression, the participants initially had a mean HRSD-24 
baseline of 28.3. Patients received ECT three times a week until they met remission criteria. If a 
patient did not meet the criteria by their 12th treatment they were considered a failure. After 
completion of the study, both electrode placements had statistically significantly decrease in 
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symptoms of depression. Bifrontal ECT placement had an average change in HRSD-24 score of 
22.2 points, from 28.1 to 6.7 (P- 0.09), and a remission rate of 100%. Bitemporal ECT placement 
had an average change in HRSD-24 score of 22.7 points, from 27.7 to 5.0 and a remission rate of 
95.8%. Table 3 shows the treatment effects of bitemporal ECT on the symptoms of depression, 
when compared to bifrontal ECT as control. Relative benefit increase (RBI) was calculated to be 
-0.04. Absolute benefit increase (ABI) was calculated to be -4.2%. Numbers needed to treat 
(NNT) was calculated as -24, indicating that for every 24 patients treated with bitemporal ECT 
one fewer would have remission of depressive symptoms by their 12th ECT treatment compared 
to bifrontal ECT treatment. 7 
Table 3: Treatment effect of bitemporal ECT on depression  
CER EER RBI ABI NNT P 
100% 95.8% -0.04 -4.2% -24 0.77 
 
The Ranjkesh6 study was a randomized control, double blind, comparison trial that randomized 
45 subjects into groups receiving bifrontal ECT (15 patients), right unilateral ECT (15 patients) 
and bitemporal ECT (15 patients), 6 patients did not complete the study, 2 from the bifrontal 
group, 1 from the bitemporal group, and 3 from the right unilateral group. “Worst-case” analysis 
was not done on the participants that did not complete the trial. There was no statistically 
significant difference between the participants of each group as analyzed with chi-square tests 
and one way analysis of variance (P> 0.05). The mean age of the participants was 34.7 years old 
and 61.5% female. In regards to the severity of their depression, the participants initially had a 
mean HRSD-24 baseline of 34.7. Patients received at least 8 ECT treatments, with the final 
HRSD-24 score recorded for the study completed after that treatment. After completion of the 
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study, all electrode placements had statistically significantly decreased the symptoms of 
depression according to the HRSD-24 score. Bifrontal ECT placement had an average change in 
HRSD-24 score of 25.7 points, from 35.0 to 9.3 (P- 0.09). Right unilateral ECT placement had 
an average change in HRSD-24 score of 24.8 points, from 32.2 to 7.4, 100% remission. 
Bitemporal ECT placement had an average change in HRSD-24 score of 24.3 points, from 32.1 
to 7.8, 100% remission. All three methods demonstrated effectiveness in reducing HRSD-24 
scores over time and treating depression, with no significant difference in one method over 
another (P > 0.05). Table 3 shows the treatment effects of bitemporal ECT on the symptoms of 
depression, when compared to bifrontal ECT as control. Relative benefit increase (RBI) was 
calculated to be 0. Absolute benefit increase (ABI) was calculated to be 0%. Numbers needed to 
treat (NNT) was calculated as 0, indicating that neither ECT electrode placement will cause more 
negative or positive outcomes to a patient. 6 
Table 4: Treatment effect of bitemporal ECT on depression  
CER EER RBI ABI NNT P 
100% 100% 0 0% 0 > 0.05 
 
DISCUSSION 
This selective evidence based medicine review investigated three randomized controlled 
trials to determine whether or not bitemporal ECT is an effective treatment for depression. All 
three studies were analyzed by comparing bitemporal ECT to bifrontal ECT. 
 All three trials concluded that when analyzed individually bitemporal ECT, and bifrontal 
ECT were effective in treating depression. When the analysis was done comparing bitemporal 
ECT to bifrontal ECT the results were inconclusive. There was a lack of studies comparing 
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bitemporal ECT to placebo in the initial search for studies, which made it necessary to compare 
bitemporal ECT to bifrontal ECT.  
 The results of the Kellner8 study are generalizable to adult patients with major depression 
and suggests that bitemporal ECT is very effective at treating depression. However the RBI of 
0.05 is small and suggests that it is not much more effective than bifrontal ECT. The ABI 
suggests that 3% of patients receiving bitemporal ECT will have improvement of their 
depression when compared to patients receiving bifrontal ECT. Some limitations of this study 
include a high drop out rate (27.4%), and the frequency of data collection (5 collections). This 
study did conclude that bitemporal ECT has more rapid symptom reduction when compared to 
bifrontal, and right unilateral ECT. 8 
 The results of the Bailine7 study are generalizable to adult patients with major depression. 
The study concluded that both bitemporal and bifrontal ECT were efficacious in treating 
depression. In this review, comparing bitemporal and bifrontal ECT an ABI of -4.2% suggests 
that bifrontal ECT will have more improvement on depression when compared to bitemporal 
ECT. The p-value in this study was 0.77, suggesting the results are not statistically significant. 
Some limitations of this study include a small sample size (58), and a high drop out rate 
(17.2%).7 
 The results of the Ranjkesh6 study are generalizable to adult patients with depression. The 
study concluded that bitemporal and bifrontal ECT are effective at treating depression in adults, 
both with 100% effectiveness. When comparing bitemporal to bifrontal ECT the RBI, and ABI 
were both 0. This is stating that there is no difference in efficacy when choosing bifrontal to 
bitemporal ECT. The p-value in this study was >0.05 making the results not statistically 
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significant.  Some limitations of this study include small sample size 45, and high drop out rate 
(13.3%).6 
CONCLUSION 
When analyzed without comparison, bitemporal ECT is effective at treating major depression. 
When bitemporal ECT is compared to bifrontal ECT the results are conflicting. Future studies 
are warranted comparing bitemporal ECT to placebo. A study of this design would be limited by 
not being able to be double blinded because it is very obvious to both the patient and clinician if 
a patient received ECT or not.   
. 
 
 
go 
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